AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ai-Media Technologies Ltd

0.205

+0.0031.23%

Volume:165.90K

Turnover:34.56K

Market Cap:43.09M

PE:-14.14

High:0.210

Open:0.200

Low:0.200

Close:0.203

52wk High:0.950

52wk Low:0.195

Shares:210.21M

Float Shares:119.50M

Volume Ratio:1.76

T/O Rate:0.14%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.014

EPS(LYR):-0.008

ROE:-4.08%

ROA:-1.84%

PB:0.60

PE(LYR):-25.60

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Ai-Media Technologies Insider Purchases Yet To Pay Off Regardless Of Recent Strength

Simply Wall St.

AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient

MT Newswires Live

AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement

MT Newswires Live

AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/AIM.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AIM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AIM.AU\",,,,,undefined,":{"symbol":"AIM.AU","market":"AU","secType":"STK","nameCN":"Ai-Media Technologies Ltd","latestPrice":0.205,"timestamp":1787724720000,"preClose":0.2025,"halted":0,"volume":165895,"delay":0,"changeRate":0.012345679012345552,"nameEN":"Ai-Media Technologies Ltd","floatShares":119502232,"shares":210206965,"eps":-0.0145,"marketStatus":"Closed","change":0.0025,"latestTime":"08-26 16:12:00 AEST","open":0.2,"high":0.21,"low":0.2,"amount":34561,"amplitude":0.049383,"askPrice":0.215,"askSize":49979,"bidPrice":0.205,"bidSize":62253,"shortable":3,"etf":0,"ttmEps":-0.0145,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.2025,"openAndCloseTimeList":[[1787702400000,1787724000000]],"volumeRatio":1.76394,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"AIM.AU","preClose":0.2025,"auctionPrice":0.205,"auctionVolume":53,"auctionTime":1787724540725,"referencePrice":0.205,"referenceTime":1787740203093,"auction":3,"marketStatus":"盘后竞价","timestamp":1787724540725}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AIM.AU\",,,,,undefined,":{"symbol":"AIM.AU","floatShares":119502232,"roa":"-1.84%","roe":"-4.08%","lyrEps":-0.008007,"volumeRatio":1.76394,"shares":210206965,"dividePrice":0,"high":0.21,"amplitude":0.049383,"preClose":0.2025,"low":0.2,"week52Low":0.195,"pbRate":"0.60","psRate":"0.69","week52High":0.95,"institutionHeld":0,"latestPrice":0.205,"committee":0.109363,"eps":-0.0145,"divideRate":0,"volume":165895,"delay":0,"ttmEps":-0.0145,"open":0.2,"prevYearClose":0.795,"prevWeekClose":0.195,"prevMonthClose":0.21,"prevQuarterClose":0.23,"fiveDayClose":0.2,"twentyDayClose":0.2,"sixtyDayClose":0.21,"earningDate":1787760000000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AIM.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"AIM.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-25","symbol":"AIM.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771974000000,"name":null,"time":"","dateTimestamp":1771938000000,"actualEps":null},{"date":"2025-08-28","symbol":"AIM.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-27","symbol":"AIM.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740610800000,"name":null,"time":"","dateTimestamp":1740574800000,"actualEps":null},{"market":"AU","date":"2024-12-31","symbol":"AIM.AU","reason":null,"defaultRemindTime":1735599600000,"announcedDate":"2024-11-26","type":"delisting","dateTimestamp":1735563600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AIM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AIM.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645005559","title":"Ai-Media Technologies Insider Purchases Yet To Pay Off Regardless Of Recent Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2645005559","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645005559?lang=en_us&edition=fundamental","pubTime":"2026-06-23 06:29","pubTimestamp":1782167394,"startTime":"0","endTime":"0","summary":"Some of the losses seen by insiders who purchased AU$562.7k worth of Ai-Media Technologies Limited ( ASX:AIM ) shares...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3112100-choice2-main-header/1585186903084","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3112100-choice2-main-header/1585186903084"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-aim/ai-media-technologies-shares/news/ai-media-technologies-insider-purchases-yet-to-pay-off-regar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-aim/ai-media-technologies-shares/news/ai-media-technologies-insider-purchases-yet-to-pay-off-regar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7064","AIM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644089856","title":"AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2644089856","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644089856?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:24","pubTimestamp":1781789085,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech  said Thursday that the last patient has received their first dose in the phase 2 DURIPANC clinical trial of Ampligen in combination with AstraZeneca's  anti-PD-L1 immune checkpoint inhibitor Imfinzi to treat metastatic pancreatic cancer.The immuno-pharma company said it expects primary endpoint analysis to begin in December, with topline results expected in Q1 of 2027. The primary endpoint is clinical benefit rate, which is the proportion of patients achieving stable disease, partial response or complete response at 24 weeks following the initiation of combination therapy.Analysis of the secondary endpoints is expected to begin in June 2027.Shares of AIM ImmunoTech were up 4% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","AZNH","LU2456880835.USD","LU1267930573.SGD","LU2462157665.USD","AIM","LU0310800379.SGD","LU2236285917.USD","LU0128525929.USD","LU2237443382.USD","LU2237443895.HKD","LU0109394709.USD","BK7064","LU0058720904.USD","LU2237443465.HKD","LU2237443549.SGD","BK4557","LU0889565916.HKD","LU0708994859.HKD","LU0320765992.SGD","AIM.AU","BK4568","LU0289739699.SGD","BK4585","LU0029864427.USD","LU2237443622.USD","LU2417539215.USD","IE00B3T34201.USD","LU1829250122.USD","BK4007","LU2237443978.SGD","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642934004","title":"AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642934004","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642934004?lang=en_us&edition=fundamental","pubTime":"2026-06-09 22:05","pubTimestamp":1781013906,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech  has launched a registered direct offering and a concurrent private placement priced at-the-market under NYSE American rules for gross proceeds of around $2.7 million, the company said Tuesday.Under the direct offering, AIM will issue and sell about 2.6 million shares at $0.5189 per share, the company said. Under the private placement, the company will issue and sell the same amount of unregistered shares and unregistered class J warrants to purchase up to 10.2 million shares, according to a statement.The class J Warrants will have an exercise price of $0.5189 per share, AIM said.The offering is expected to close on or about Wednesday, the company said.AIM said it intends to use the net proceeds for the manufacture of clinical drug supply, its current clinical trial activities, its planned Phase 3 clinical trial activities, and working capital purposes.Price: 0.43, Change: -0.08, Percent Change: -15.64","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AIM.AU","BK4557","BK7064","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641381482","title":"AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2641381482","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641381482?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:01","pubTimestamp":1780923719,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech  said Monday that its metastatic pancreatic cancer drug Ampligen has shown \"positive progress\" in an ongoing phase 2 study.According to the company, the study is showing overall median survival of 34.8 months, compared with 12.5 months for historical controls in one group of study patients with a specific immune marker.The specific indication for the trial is patients with stable disease after Folfirinox standard of care. The company said it remains on track for a planned December evaluation of the 25-patient trial's primary endpoint of clinical benefit rate at six months.Shares of AIM rose more than 26% in recent premarket trading Monday.Price: 0.6520, Change: +0.135, Percent Change: +26.02","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2065732104.USD","AIM","BK4139","BK4557","AIM.AU","BK7064","PRGS","BK4097"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AIM.AU\",params:#limit:6,delay:true,,,undefined,":[]}}